HR 3379 · 116th Congress · Health

PRICED Act

Introduced 2019-06-20· Sponsored by Rep. Schakowsky, Janice D. [D-IL-9]· House

Bill Progress

✓
Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Referred to the Subcommittee on Health.(2019-06-21)

Plain Language Summary

[AI summary unavailable — showing source text] Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period. This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.…

Summarized by Claude AI · Non-partisan · For informational purposes only

Cosponsors (20)

19 Democrats1 Republican
Rep. Westerman, Bruce [R-AR-4]AR
Rep. DeLauro, Rosa L. [D-CT-3]CT
Rep. Craig, Angie [D-MN-2]MN
Rep. Doggett, Lloyd [D-TX-35]TX
Rep. Krishnamoorthi, Raja [D-IL-8]IL
Rep. Khanna, Ro [D-CA-17]CA
Rep. Cicilline, David N. [D-RI-1]RI
Rep. Pocan, Mark [D-WI-2]WI
Rep. Rush, Bobby L. [D-IL-1]IL
Rep. Levin, Andy [D-MI-9]MI
Rep. Morelle, Joseph D. [D-NY-25]NY
Rep. Jayapal, Pramila [D-WA-7]WA
Rep. Tlaib, Rashida [D-MI-13]MI
Rep. Kaptur, Marcy [D-OH-9]OH
Rep. Welch, Peter [D-VT-At Large]VT
Rep. Garcia, Jesus G. "Chuy" [D-IL-4]IL
Rep. Ocasio-Cortez, Alexandria [D-NY-14]NY
Rep. Lee, Barbara [D-CA-13]CA
Rep. Chu, Judy [D-CA-27]CA
Del. Norton, Eleanor Holmes [D-DC-At Large]DC